科伦博泰生物-B(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准第四项适应症上市，用于治疗2L+HR+/HER2-乳腺癌

智通财经02-06

智通财经APP讯，科伦博泰生物-B(06990)发布公告，近日，本公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱®)的一项新增适应症上市申请已获中国国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609639435?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-06 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609639435","market":"fut","top_or_hot":-1,"title":"科伦博泰生物-B(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准第四项适应症上市，用于治疗2L+HR+/HER2-乳腺癌","media":"智通财经","content":"<div>\n<p>智通财经APP讯，科伦博泰生物-B(06990)发布公告，近日，本公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱®)的一项新增适应症上市申请已获中国国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402529.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰生物-B(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准第四项适应症上市，用于治疗2L+HR+/HER2-乳腺癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰生物-B(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准第四项适应症上市，用于治疗2L+HR+/HER2-乳腺癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-06 16:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1402529.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，科伦博泰生物-B(06990)发布公告，近日，本公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱®)的一项新增适应症上市申请已获中国国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402529.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4203","symbol_name":"医疗保健房地产投资信托","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1402529.html","article_id":"2609639435","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609639435","pubTimestamp":1770366971,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，科伦博泰生物-B 发布公告，近日，本公司靶向人滋养细胞表面抗原2的抗体偶联药物芦康沙妥珠单抗(佳泰莱)的一项新增适应症上市申请已获中国国家药品监督管理局批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子受体2阴性乳腺癌成人患者。此次获批的至少经一线化疗治疗HR+/HER2-BC是芦康沙妥珠单抗在中国上市的第四项适应症。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4203":"医疗保健房地产投资信托","06990":"科伦博泰生物-B","BK4225":"医疗保健房地产信托","HR":"医疗保健房地产信托","BK1161":"生物科技","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC"},"translate_title":"Kelunbotai Bio-B (06990): The core product TROP2ADC Luconsartuzumab (sac-TMT) was approved by the National Medical Products Administration for the fourth indication for the treatment of 2L + HR +/HER2-breast cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1.5,"HR":1.5},"content_text":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，近日，本公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱®)的一项新增适应症上市申请已获中国国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子受体2阴性(HER2-)(免疫组织化学(IHC)0、IHC1+或IHC2+/原位杂交(ISH)-)乳腺癌(BC)成人患者。此次获批的至少经一线化疗治疗HR+/HER2-BC是芦康沙妥珠单抗(sac-TMT)在中国上市的第四项适应症。本次获批基于OptiTROP-Breast023期临床研究的积极结果，该研究已在2025年欧洲肿瘤内科学会(ESMO)大会入选最新突破性摘要(LBA)并以口头报告的形式发布。OptiTROP-Breast02研究评估芦康沙妥珠单抗(sac-TMT)单药对比研究者选择化疗用于治疗不可切除或转移性的HR+/HER2-BC患者的有效性和安全性。本项3期研究入组患者中，95.7%的患者入组时存在内脏转移，75.9%的患者存在肝转移;52.9%的患者入组时HER2表达为0(IHC0)，47.1%的患者入组时HER2为低表达(IHC1+或IHC2+/ISH-);所有患者既往接受过CDK4/6抑制剂和紫杉烷类药物治疗。在晚期或转移性阶段，56.6%的患者既往接受过≥2线化疗方案治疗。结果显示，芦康沙妥珠单抗(sac-TMT)组盲态独立评审委员会(BIRC)评估的无进展生存期(PFS)相较于化疗组显示出具有显著统计学意义和临床意义的改善(8.3个月vs.4.1个月;风险比(HR)，0.35;95%置信区间(CI)：0.26-0.48;p<0.0001);在预先设定的各亚组中均观察到一致的PFS获益，包括HER2表达为0及HER2低表达、晚期或转移性阶段接受化疗线数、基线有无内脏转移、基线肝转移、既往CDK4/6抑制剂治疗时长。BIRC评估的PFS结果显示，HER2表达为0和HER2低表达(IHC1+或IHC2+/ISH-)亚组中，HR分别为0.39(95%CI：0.26-0.57)和0.31(95%CI：0.20-0.48)。同时相较于化疗组，显示总生存期(OS)的获益趋势以及客观缓解率(ORR)明显提升(41.5%vs24.1%)。目前，芦康沙妥珠单抗(sac-TMT)联合╱不联合帕博利珠单抗(可瑞达®2)用于治疗既往接受过内分泌治疗但未接受过化疗的HR+/HER2-BC患者的全球(NCT06312176)和中国(NCT07071337)的3期临床研究均已启动。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609639435","isCrawlerRequest":true}